Abstract:Liver fibrosis refers to the process underlying the development of chronic liver diseases, wherein liver cells are repeatedly destroyed and regenerated, which leads to an excessive deposition and abnormal distribution of the extracellular matrix such as collagen, glycoprotein and proteoglycan in the liver. Liver fibrosis thus constitutes the pathological repair response of the liver to chronic injury. Hepatic fibrosis is a key step in the progression of chronic liver disease to cirrhosis and an important factor affecting the prognosis of chronic liver disease. Further development of liver fibrosis may lead to structural disorders of the liver, nodular regeneration of hepatocytes and the formation of cirrhosis. Hepatic fibrosis is histologically reversible if treated aggressively during this period, but when fibrosis progresses to the stage of cirrhosis, reversal is very difficult, resulting in a poor prognosis. There are many causes of liver fibrosis, including liver injury caused by drugs, viral hepatitis, alcoholic liver, fatty liver and autoimmune disease. The mechanism underlying hepatic fibrosis differs among etiologies. The establishment of an appropriate animal model of liver fibrosis is not only an important basis for the in-depth study of the pathogenesis of liver fibrosis but also an important means for clinical experts to select drugs for the prevention and treatment of liver fibrosis. The present study focused on the modeling methods and fibrosis characteristics of different animal models of liver fibrosis, such as a chemical-induced liver fibrosis model, autoimmune liver fibrosis model, cholestatic liver fibrosis model, alcoholic liver fibrosis model and non-alcoholic liver fibrosis model. In addition, we also summarize the research and application prospects concerning new organoids in liver fibrosis models proposed in recent years. A suitable animal model of liver fibrosis and organoid fibrosis model that closely resemble the physiological state of the human body will provide bases for the in-depth study of the pathogenesis of liver fibrosis and the development of therapeutic drugs.

Animal and Organoid Models of Liver Fibrosis

Synergistic Modulation of a Tunable Microenvironment to Fabricate a Liver Fibrosis Chip for Drug Testing.

Generation of Fibrotic Liver Organoids Using Hepatocytes, Primary Liver Sinusoidal Endothelial Cells, Hepatic Stellate Cells, and Macrophages

Three-Dimensional Organoids as a Model to Study Nonalcoholic Fatty Liver Disease

Mice Hepatic Organoids for Modeling Nonalcoholic Fatty Liver Disease and Drug Response

Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases

Research progress on rodent models and its mechanisms of liver injury

Animal Models of Chronic Liver Diseases.

Animal Models Of Chronic Liver Diseases

Liver Fibrosis in Fish Research: from an Immunological Perspective

Insight to Biofabrication of Liver Microtissues for Disease Modeling: Challenges and Opportunities

Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy

Research progress and application of liver organoids for disease modeling and regenerative therapy

Development and Validation of a Primate Model for Liver Fibrosis.

Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?

Liver fibrosis: Pathophysiology and clinical implications

Constructing biomimetic liver models through biomaterials and vasculature engineering

Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids

A decade of liver organoids: Advances in disease modeling

Human Liver Organoid: Modeling Liver Steatosis and Beyond

Two-dimensional vascularized liver organoid on extracellular matrix with defined stiffness for modeling fibrotic and normal tissues